Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.41 |
| ▸ | PRPS1 | P60891 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL128435 | 0.78 | DDB1 (0.42) | MEN1KMT2ADDB1CRBNKDM4E | |
| SCHEMBL29435809 | 0.76 | DDB1 (0.41) | DDB1CRBNKDM4EALDH1A1GLA | |
| SCHEMBL16782354 | 0.76 | DDB1 (0.41) | DDB1CRBNKDM4EALDH1A1GLA | |
| SCHEMBL358722 | 0.76 | DPP4 (0.44) | DDB1CRBNKDM4EALDH1A1GLA | |
| SCHEMBL3185680 | 0.76 | DDB1 (0.41) | DDB1CRBNKDM4EALDH1A1GLA | |
| SCHEMBL23022464 | 0.76 | DDB1 (0.41) | DDB1CRBNKDM4EALDH1A1GLA | |
| SCHEMBL19848258 | 0.76 | DDB1 (0.41) | DDB1CRBNKDM4EALDH1A1GLA | |
| SCHEMBL9981117 | 0.76 | GRM2 (0.45) | DDB1CRBNPRPS1KDM4EALDH1A1 | |
| SCHEMBL29070737 | 0.76 | SMN1; SMN2 (0.41) | MEN1KMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL5003525 | 0.76 | SMN1; SMN2 (0.46) | PRPS1ALDH1A1GAANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239801-A1 | PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2024-07-18 | — | — | US | disclosed |
| US-20240239801-A1 | PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2024-07-18 | — | — | US | disclosed |
| US-20240217971-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | Université de Montréal (CA) | 2024-07-04 | — | — | US | disclosed |
| WO-2024077391-A1 | THIAZOLO[5,4-D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | UNIVERSITE DE MONTREAL (CA) | 2024-04-18 | — | — | WO | disclosed |
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2020-08-25 | — | — | US | disclosed |
| EP-3467930-B1 | NONAQUEOUS ELECTROLYTE AND NONAQUEOUS SECONDARY BATTERY | ASAHI CHEMICAL IND (JP) | 2020-05-13 | — | — | EP | disclosed |
| EP-3467930-A1 | NONAQUEOUS ELECTROLYTE AND NONAQUEOUS SECONDARY BATTERY | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2019-04-10 | — | — | EP | disclosed |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
| WO-2008084218-A1 | BENZAZOLE DERIVATIVES FOR THE TREATMENT OF INFLAMMATIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | BPTF, BRD4, KCNN2 | MEN1 1058/4885KMT2A 458/4885DDB1 1646/4885 |
| US-20240239801-A1 | PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | NRAS, BRAF, KRAS | MEN1 2257/4885KMT2A 2665/4885DDB1 610/4885 |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | BPTF, BRD4, KCNN2 | MEN1 1058/4885KMT2A 458/4885DDB1 1646/4885 |
| US-20240217971-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | BRAF, NRAS, DPYD | MEN1 1888/4885KMT2A 2305/4885DDB1 1115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.